Abstract The aim of this work was to study time trends of antidepressant drug (AD) prescriptions in a geographically defined US population between 2005 and 2011 for men and women separately. Using the Rochester Epidemiology Project medical records-linkage system, we identified all Olmsted County, MN residents who received AD outpatient prescriptions between 2005 and 2011 (7 years). We calculated the annual age-and sex-specific prevalence over 7 years and used generalized estimating equation models to test for time trends. The prevalence of subjects receiving at least one AD prescription was approximately two times higher in women than in men consistently across the 7 years of the study. The standardized annual prevalence increased from 10.8 % in 2005 to 14.4 % in 2011 overall, from 7.0 % in 2005 to 9.9 % in 2011 for men, and from 14.4 % in 2005 to 18.6 % in 2011 for women. The absolute percent increase was greater in women (4.2 vs. 2.9 %; standardized); however, the relative percent increase was greater in men (41.4 vs. 29.2 %; standardized). The relative percent increase was greater in the age group 65+ years for both men and women. AD prescriptions are increasing over time, especially in the elderly. Women receive more AD prescriptions than men. However, the relative increase in AD prescriptions over time is greater in men than women.
Introduction
During the past two decades, there has been a dramatic increase in the use of antidepressant drugs (AD) (Mojtabai 2008; Olfson and Marcus 2009) . Many factors may have influenced the increase in AD use, including increased recognition and more aggressive treatment of depression, approval of new AD drugs, direct-to-consumer advertising, off label use of AD for conditions such as chronic pain or sleep problems, and changing advisories from federal or local regulatory agencies (Compton et al. 2006 ). Two recent surveys of selfreported use indicated that the yearly rate of AD use increased from 5.8 % in 1996 to 10.1 % in 2005, and the monthly rate of AD use increased from 1. 8 % in 1988-1994 to 8.9 % in 2005-2008 (National Center for Health Statistics 2012; Olfson and Marcus 2009) .
Although there have been major changes in development, admission to the market, and withdrawal from the market of AD medications over the last decade, there is little published literature on recent trends in AD prescriptions in the USA (Harman et al. 2009 ). In addition, although the overall use of AD has generally increased over time, there is mounting concern that this overall trend fails to capture underuse by traditionally disadvantaged populations (Harman et al. 2009 ). Therefore, the purpose of this study was to describe age-and sex-specific time trends in AD prescriptions for all indications (not just depression) in a geographically defined US population between 2005 and 2011.
Materials and methods

Setting and population
We used the resources of the Rochester Epidemiology Project (REP) medical records-linkage system to identify all Olmsted County, MN residents who received at least one AD prescription between 2005 and 2011. Details about the REP have been described previously (Rocca et al. 2012; St Sauver et al. 2011 , 2012a . In brief, the REP is a research infrastructure that links medical record information from the local health care providers in Olmsted County, MN. Due to the relative isolation of the county from major metropolitan areas, and to the presence of a major referral medical center (Mayo Clinic), almost all residents seek health care from a limited number of health care providers. The REP captures information on residents as they visit their health care providers for routine medical care. This medical records-linkage system is unique in its capture of virtually all health care information delivered to an entire population, regardless of age, sex, or insurance status (Rocca et al. 2012; St Sauver et al. 2011 , 2012a .
Measures
Outpatient prescription records from health care providers in Olmsted County were electronically available from 2005 to 2011 (7 years). Prescriptions were coded using the RxNorm classification system and were further grouped into categories using the National Drug File-Reference Terminology (NDF-RT) classification (Pathak et al. 2011; Zhong et al. 2013) . We considered all AD prescriptions, including transdermal patches. We grouped AD medications into five categories: (1) tricyclic antidepressants: amitriptyline, clomipramine, desipramine, doxepin, amoxapine, imipramine, maprotiline (tetracyclic), nortriptyline, protriptyline, and trimipramine; (2) monoamine oxidase inhibitors: phenelzine, selegiline, and tranylcypromine; (3) selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vilazodone; (4) serotonin-norepinephrine reuptake inhibitors: desvenlafaxine, duloxetine, milnacipran, and venlafaxine; and (5) others: bupropion, mirtazapine, nefazodone, and trazodone.
Statistical analyses
The age-and sex-specific prevalence of subjects receiving at least one AD prescription in each calendar year was calculated by dividing the number of people who received an AD prescription by the total corresponding age-and sex-specific population for that year (Zhong et al. 2013 ). Age-standardized, or age-and sex-standardized, annual prevalence figures were obtained by direct standardization to the US total population (2000 US Census; using the seven age groups listed in Table 1 ). These standardized prevalence figures were intended for internal comparison across calendar years, not as national projections.
We used generalized estimating equation (GEE) models with a negative binomial distribution to test for temporal trends in antidepressant prescriptions overall and by selected categories (Frome and Checkoway 1985; Gardner et al. 1995; McCullagh and Nelder 1983) . Specific counts for each calendar year, age (using the seven age groups listed in Table 1) , and sex were used as the unit of observation. Percent change for the entire study period was also estimated using the GEE models. Comparisons of temporal trends across specific groups (e.g., men vs. women) were performed by including a two-way interaction term (in models including also the main effects). Because the graphical assessment suggested that the rate of change differed between the 2005-2007 and the 2008-2011 time periods, a quadratic term for calendar year was included in all models.
To address the problem of subjects receiving only one prescription that was never refilled, we conducted a set of sensitivity analyses restricted to subjects who received two or more prescriptions. To provide a window of 5 years in which 
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Results
Prevalence by age and sex Table 1 shows the age-specific prevalence of AD prescriptions for each of the 7 years of the study for men and women separately and combined. The age-and sexspecific prevalence at the beginning of the study (2005; left panel) and at the end of the study (2011; right panel) are also shown graphically in Fig. 1 . For all study years and for all ages after age 12 years, the prevalence was higher for women than for men. In each calendar year, the age-specific prevalence of prescriptions in women increased from age 5-12 to age 50-64 years and declined slightly or remained stable in the 65+ year group (Fig. 1) . Similarly, the age-specific prevalence in men increased from age 5-12 to age 50-64 years and declined slightly or remained stable in the 65+ year group in 2005 through 2007 ( Fig. 1; left panel) ; however, the age-specific prevalence in men continued to increase in the age group 65+ years in 2008 through 2011 ( Fig. 1; right panel) . In sensitivity analyses restricted to subjects who had two or more AD prescriptions within a 5-year time window, the overall prevalence of subjects with AD prescriptions reduced from 11.3 to 10.6 % in 2007, from 12.1 to 11.4 % in 2008, and from 13.5 to 12.7 % in 2009 (crude prevalence; data not shown in Table 1 ).
Time trends by age and sex Figure 2 shows the time trends of AD prescriptions for any indication between 2005 and 2011 for men and women in five age groups and overall (lower right panel). Consistently across the 7 years of the study, the annual prevalence of AD prescriptions was approximately two times higher in women compared to men (Table 1 and Fig. 2) . The ageand sex-adjusted prevalence of subjects receiving at least one AD prescription increased from 10.8 % in 2005 to 14.4 % in 2011 overall, from 14.4 to 18.6 % in women, and from 7.0 to 9.9 % in men ( Table 1 ). The test for linear trend over calendar year was significant for both men (p= 0.03) and women (p=0.01; all models included a quadratic term for calendar year). Although the absolute change in standardized prevalence over the 7 years of the study was greater for women (4.2 %) than for men (2.9 %), the relative increase (in percent of the 2005 prevalence) was greater for men (41.4 %) than for women (29.2 %; sex by calendar year interaction, p=0.0003). The relative percent increase per year estimated by the regression model was 5.7 % overall, and was greater in 2008-2011 (6.1 %) than in 2005-2007 (1.7 %). The rapid increase in AD prescriptions between 2008 and 2011 was attributable primarily to an increased number of prescriptions to Olmsted County men and women in the age groups 50-64 years and 65+ years (Table 1 and Fig. 2 ). In particular, the largest increase in AD prescriptions from 2005 through 2011 was observed in the age group 65+ years, from 14.6 % in 2005 to 23.1 % in 2011 for both sexes combined (Table 1 and from 3.5 to 4.8 % for "other AD" and from 1.2 to 1.8 % for serotonin-norepinephrine reuptake inhibitors. The increase in prevalence of tricyclic antidepressants and monoamine oxidase inhibitors prescriptions was negligible (0.2 %).
Discussion
Our population-based study showed that the prevalence of AD prescriptions for all indications (not just depression) was about two times higher in women than in men throughout the entire study period. This finding confirms a number of recent studies that showed a higher use of AD in women compared to men (Athanasopoulos et al. 2013; Atlantis et al. 2012; Kuo et al. 2011; Lockhart and Guthrie 2011; Meng et al. 2013; Mojtabai and Olfson 2014; Parabiaghi et al. 2011; Sundell et al. 2011; Wu et al. 2012) . We also observed that the prevalence of AD prescriptions reached a peak at age 50-64 years in women but not in men. This age group corresponds approximately with the early postmenopausal years (the median age at menopause in the USA is 51 years) (Shuster et al. 2010 ). This pattern may suggest a causal link between the endocrinological changes of menopause and the exacerbation of existing depressive symptoms or the appearance of de novo depressive symptoms (Rocca et al. 2008; Shuster et al. 2010) . AD prescriptions increased steadily from 2005 to 2011, similar to trends observed in previous studies from earlier time frames (Mojtabai 2008; Olfson and Marcus 2009) . Although women experienced a greater absolute increase in prescriptions between 2005 and 2011, the relative increase over time was significantly greater in men compared with women. Interestingly, the increase in AD prescriptions was mostly driven by prescriptions to older adults, particularly after 2007. Nearly 1 in 4 Olmsted County residents aged 65+ years received at least one AD prescription in 2011. The relative increase in AD prescriptions in residents aged 65+ was similar in men and women.
In our study population, the most commonly prescribed ADs were selective serotonin reuptake inhibitors, and the increase in AD prescriptions was mostly confined to this drug group. Citalopram, which may be used to treat multiple disorders, had both the highest prevalence and the greatest increase in prevalence over time. These data are in agreement with a previous national survey that showed that about 67 % of all AD prescriptions in 2005 were for selective serotonin reuptake inhibitors (Olfson and Marcus 2009) .
Our study revealed a greater relative increase in prescriptions in men compared to women. This trend may suggest that the care-seeking behavior in men has improved over time reducing the underdiagnosis and the undertreatment of anxiety and depressive disorders in men. We also observed a significant increase in prescriptions of ADs to the elderly population. Depression in older adults has been historically underdiagnosed and undertreated; (Lavretsky and Kumar 2002) however, our data suggest that these practices may be changing. The reasons for the rapid increase in AD prescriptions among persons 65 years of age and older from 2008-2011 are not clear. One possible explanation is that many selective serotonin reuptake inhibitors became available generically just prior to this time frame (e.g., paroxetine in 2003, citalopram in 2004, and sertraline in 2006) . The lower cost, combined with new information about the safety and efficacy of selective serotonin reuptake inhibitors in the elderly, may have also contributed in part to this increase (Mottram et al. 2006) .
A second possible explanation is the US Food and Drug Administration (FDA) advisory released in May 2007 (Friedman and Leon 2007) reporting an increased risk of suicidal thoughts and behaviors among young adults aged 18-24 years taking antidepressants, but not among adults older than 24 years. The FDA advisory also emphasized the increased risk of suicide among adults 65 or older who were not treated for depression. This important FDA statement may have encouraged physicians to prescribe AD to the elderly (Lineberry et al. 2007) . However, further studies are needed to validate this hypothesis.
A third possible explanation for the increased AD prescriptions in this community may have been the release of new national recommendations for depression screening in adults in December, 2009 (Whitlock et al. 2010 . Olmsted County medical care providers began routine depression screening programs at this time. In addition, the Depression Improvement Across Minnesota, Offering a New Direction (DIAMOND) program was launched in 2008 (https://www. icsi.org/health_initiatives/mental_health/diamond_for_ depression/) to increase the treatment of adults with known and previously diagnosed depression.
A first important limitation of our study is the geographic specificity of the sample. Our study was based on a single Midwestern county, and our findings may not apply to other communities in the US with different demographic and socioeconomic characteristics and different access to health care. On the other hand, we have previously reported that the population of Olmsted County is comparable to the population of Minnesota, of the Upper Midwest, and of a large segment of the entire US population (St Sauver et al. 2012a ). The age-standardized and age-and sex-standardized prevalence figures reported in Table 1 are only intended for internal comparison across the seven calendar years. Extrapolations and generalizations from this study, or from any other study in a single selected population, to the entire US population must be judged considering specific demographic, socioeconomic, or medical practice differences. Our findings from a geographically defined population are most useful when they are compared with findings from other populations in the USA or worldwide to investigate geographic similarities or differences in patterns of AD prescriptions. Geographic similarities or differences can be used to guide our decisions in clinical practice or in public health (St Sauver et al. 2012a) .
A second limitation of our study is that we included all AD prescriptions irrespective of the indications for the prescription or of the duration of treatment. ADs are often prescribed for conditions other than depression, including anxiety, sleep problems, smoking cessation, and pain. It was not possible to assess and validate the indications for the thousands of patients included in this study. Further studies are ongoing in an effort to validate indications and duration of use in samples of the total resident population included in this paper. Third, we may have underestimated the prevalence of AD prescriptions because we did not include data from a few local psychiatrists and AD prescriptions given during hospitalizations. However, this underestimation should be minimal.
Fourth, our study examined the frequency of prescriptions, which is a useful measure of the prescribing behavior of physicians. However, it was not possible to determine whether the prescriptions were filled and taken by patients (Zhong et al. 2013) . In a set of sensitivity analyses restricted to subjects who had two or more AD prescriptions within a 5-year time window, the reduction in overall prevalence (compared with the prevalence including also subjects who had only one prescription) was small. These findings suggest that it was uncommon for subjects to receive a single isolated AD prescription without subsequent refills, and that our prevalence of AD prescriptions may be a reasonable surrogate for the prevalence of use.
Strengths of this study include the ability to capture health information on a complete Midwestern population using the REP medical records-linkage system (Rocca et al. 2012; St Sauver et al. 2011 , 2012a Zhong et al. 2013 ). Due to the relative geographical isolation of Olmsted County from major metropolitan areas, virtually all of the county residents receive health care from a few local health care providers; therefore, our findings can be considered population-based (Rocca et al. 2012; St Sauver et al. 2011 , 2012a . In addition, this population has adequate access to a full spectrum of psychiatric care including child and adolescent services.
Conclusion
We found that the annual prevalence of AD prescriptions was higher in women than men at all ages after age 12 years, and it increased steadily between 2005 and 2011. The relative increase in prescriptions over 7 years was mainly driven by increased prescriptions to the elderly, especially after 2007, and was greater in men compared with women. These trends should be monitored in the future, and patterns of underutilization or overutilization by sex, age, socioeconomic status, insurance status, and other determinants should be investigated.
